Log in

NASDAQ:ANGOAngioDynamics Stock Price, Forecast & News

$9.31
+0.18 (+1.97 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.03
Now: $9.31
$9.36
50-Day Range
$8.26
MA: $9.50
$10.69
52-Week Range
$7.48
Now: $9.31
$19.59
Volume237,900 shs
Average Volume303,581 shs
Market Capitalization$352.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.62
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. It also offers thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. In addition, the company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; and Asclera injection for treating uncomplicated spider and reticular veins of the lower extremities. Further, it provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation system; and radiofrequency ablation products for ablating solid cancerous or benign tumors. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Read More
AngioDynamics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.14 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$264.16 million
Cash Flow$5.09 per share
Book Value$12.12 per share

Profitability

Net Income$-165,790,000.00

Miscellaneous

Employees1,050
Market Cap$352.56 million
Next Earnings Date10/1/2020 (Estimated)
OptionableOptionable
$9.31
+0.18 (+1.97 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

How has AngioDynamics' stock price been impacted by Coronavirus (COVID-19)?

AngioDynamics' stock was trading at $10.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANGO stock has decreased by 8.2% and is now trading at $9.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AngioDynamics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AngioDynamics
.

When is AngioDynamics' next earnings date?

AngioDynamics is scheduled to release its next quarterly earnings announcement on Thursday, October 1st 2020.
View our earnings forecast for AngioDynamics
.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings results on Thursday, July, 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.06). The medical instruments supplier had revenue of $58.30 million for the quarter, compared to analysts' expectations of $62.86 million. AngioDynamics had a positive return on equity of 0.62% and a negative net margin of 62.76%. The company's revenue for the quarter was down 18.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.25 EPS.
View AngioDynamics' earnings history
.

What price target have analysts set for ANGO?

2 analysts have issued twelve-month price objectives for AngioDynamics' stock. Their forecasts range from $14.00 to $21.00. On average, they anticipate AngioDynamics' stock price to reach $17.50 in the next year. This suggests a possible upside of 88.0% from the stock's current price.
View analysts' price targets for AngioDynamics
.

Has AngioDynamics been receiving favorable news coverage?

Media coverage about ANGO stock has been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AngioDynamics earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about AngioDynamics
.

Are investors shorting AngioDynamics?

AngioDynamics saw a decrease in short interest in February. As of February 15th, there was short interest totaling 1,030,000 shares, a decrease of 19.5% from the January 31st total of 1,280,000 shares. Based on an average trading volume of 302,800 shares, the short-interest ratio is currently 3.4 days. Currently, 2.8% of the company's stock are sold short.
View AngioDynamics' Short Interest
.

Who are some of AngioDynamics' key competitors?

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Intel (INTC), Oasis Petroleum (OAS), General Electric (GE), Freeport-McMoRan (FCX), FireEye (FEYE), Marathon Oil (MRO), Ring Energy (REI) and Ring Energy (REI).

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the following people:
  • Mr. James C. Clemmer, CEO, Pres & Director (Age 55)
  • Mr. Michael C. Greiner, Exec. VP & CFO (Age 46)
  • Mr. David D. Helsel, Sr. VP of Global Operations and R&D (Age 55)
  • Mr. Stephen A. Trowbridge, Sr. VP & Gen. Counsel (Age 45)
  • Mr. Robert A. Simpson, Sr. VP & GM of Vascular Interventions and Therapies (Age 47)

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (12.80%), Prudential Financial Inc. (2.11%), Tributary Capital Management LLC (1.82%), Heartland Advisors Inc. (1.61%), Assenagon Asset Management S.A. (1.40%) and Nordea Investment Management AB (1.23%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould, Michael Greiner and Stephen A Trowbridge.
View institutional ownership trends for AngioDynamics
.

Which major investors are selling AngioDynamics stock?

ANGO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Heartland Advisors Inc., Aigen Investment Management LP, 6 Meridian, Synovus Financial Corp, State of Tennessee Treasury Department, Texas Permanent School Fund, and Pitcairn Co..
View insider buying and selling activity for AngioDynamics
.

Which major investors are buying AngioDynamics stock?

ANGO stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Nordea Investment Management AB, Grantham Mayo Van Otterloo & Co. LLC, Federated Hermes Inc., Lapides Asset Management LLC, Candriam Luxembourg S.C.A., Prudential Financial Inc., and Tributary Capital Management LLC. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics
.

How do I buy shares of AngioDynamics?

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AngioDynamics' stock price today?

One share of ANGO stock can currently be purchased for approximately $9.31.

How big of a company is AngioDynamics?

AngioDynamics has a market capitalization of $352.56 million and generates $264.16 million in revenue each year. The medical instruments supplier earns $-165,790,000.00 in net income (profit) each year or $0.09 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.

What is AngioDynamics' official website?

The official website for AngioDynamics is www.angiodynamics.com.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.